Mark Wildgust, Vice President, Global Medical Affairs, Oncology at The Janssen Pharmaceutical Companies of Johnson and Johnson, shared a post on LinkedIn:
“Our ambition is bold. Our science is strong. Our commitment is unwavering. Our CEO Joaquin Duato is crystal clear.
We are seeing the results of our efforts with improved patient outcomes. At every level within Johnson & Johnson Innovative Medicine we are working to Get In Front of Cancer.